About Telesis Bio
Telesis Bio is a publicly listed company based in San Diego (United States) founded in 2013. Telesis Bio has raised $25 million across 2 funding rounds from investors including Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences. Telesis Bio has completed 1 acquisition, including Eton Bioscience. Its chief executive, as recorded, is Todd R Nelson. Telesis Bio offers products and services including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Diversified and Genomics. Its legal entity is TELESIS BIO INC. Its competitors include Amyris, AskBio and Quanterix; 3 of its 3 listed competitors have raised funding.
Company details
Online platform offering life sciences reagents and kits. The companys products include the BioXp system, BioXp kits, and Benchtop reagents. Also, it develops vaccines, therapeutics, and diagnostics to combat the COVID-19 pandemic.
- Headquarters San Diego, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website telesisbio.com
- Social LinkedIn X Facebook
- Legal Name Telesis Bio, Inc.
- Annual Revenue$27.51 M (USD)0.27as on Dec 31, 2023
- Net Profit-$47.72 M (USD)1.54as on Dec 31, 2023
- EBITDA-$31.05 M (USD)28.81as on Dec 31, 2023
- Total Equity Funding$25M (USD)
in 2 rounds
- Latest Funding Round$28M (USD), Post-IPO
May 2023
- InvestorsOxford Finance
& 4 more
- Investments & Acquisitions
Products & Services of Telesis Bio
Telesis Bio offers a comprehensive portfolio of products and services, including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA.
Fully automated tool for DNA and mRNA synthesis in research labs
Compact system for gene assembly and amplification processes
Scalable device for large-scale DNA workflows
Technique for efficient DNA fragment assembly in experiments
Funding Insights of Telesis Bio
Telesis Bio has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25M
- Total Rounds 2
- Last Round Post-IPO — $28M
- First Round $25M
(Sep 2019)
- Investors Count 5
All 2 funding rounds of Telesis Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $28M | Post-IPO | – | – | |
| Sep 2019 | $25M | Series A | – | Northpond Ventures |
5 investors in total: 5 institutional.
Investors in Telesis Bio
Telesis Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Investment banking services are offered in the United States. | 2006 | broadoak.com | Bethesda, United States | |
Investor details for Telesis Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Telesis Bio
16 people are tracked at Telesis Bio (9 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Todd R Nelson | CEO | Leadership |
Vinnie Nijor | Head Of Business Development | Leadership |
Krishna Kannan | Vice President, Product And Operations | Leadership |
Daniel Gibson | Chief Technology Officer | Leadership |
☆Jen Turbiak Carroll☆ | Vice President, Investor Relations & Corporate Communications | Leadership |
Eric Esser | President And CEO At Telesis Bio | Leadership |
Richard San Pietro | Head of Intellectual Property | Leadership |
Rocky McDonald | Sr. VP Finance | Leadership |
Michael Nemzek | Chief Commercial Officer | Leadership |
Margaret Dunbar | Consulting Legal Counsel | Team |
Ali N. | Staff Scientist, Product Development | Team |
Chirag Vazirani | Scientist | Team |
Jehan Yousif Azeez | Senior Research Associate | Team |
Krithika Rajagopalan | Senior Scientist | Team |
Qi Zhang | Senior Scientist | Team |
Nasim Nabiyouni (She/her) | Commercial Project Manager | Team |
Complete people profiles for Telesis Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Telesis Bio
Telesis Bio is a publicly listed company on the OTC with ticker symbol TBIO in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jun 2021
- Listed onNASDAQ: DNAY
- Listed entityTelesis Bio, Inc.
- Exchange sectorCommercial services
- ISINUS1920032000
- Share price$0.01 · 2026-10-13
- Market capitalisation$862,329.00
- Volume (last session)2,059
Financials of Telesis Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | $27.5M | -$47.7M | -$31.1M |
| 2022 | $27.4M | -$48.5M | -$43.6M |
| 2021 | $11.0M | -$39.0M | -$33.8M |
Detailed financial statements for Telesis Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Telesis Bio
Telesis Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eton Bioscience.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
DNA sequencing products and genomic services are developed and provided. | etonbio.com | San Diego, United States | 2003 | Nov 2021 | $13M |
Complete acquisition details for Telesis Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Telesis Bio
5 dated milestones of Telesis Bio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Telesis Bio is founded.
- Funding First funding round of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Eton Bioscience.
- Funding Latest funding round, Post-IPO, of $28.0M.
Competitors of Telesis Bio
Telesis Bio has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Quanterix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. |
Detailed competitors of Telesis Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Telesis Bio
The website of Telesis Bio (telesisbio.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▼ 4.1% vs previous month
Websites whose visitors overlap most with Telesis Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sharebiology.com | sharebiology.com | 100% | #1,923,209 | – | |
molecularcloud.org | molecularcloud.org | 95% | #1,358,986 | – | |
barricklab.org | barricklab.org | 84% | #1,344,964 | – | |
addgene.org | addgene.org | 74% | #84,256 | – | |
| snapgene.com | 74% | 195.8K | #215,561 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Telesis Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Telesis Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Telesis Bio
Complete news archive for Telesis Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Telesis Bio
Telesis Bio was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Telesis Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Todd R Nelson is the CEO of Telesis Bio, as recorded in our data.
Telesis Bio is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Sep 2019.
Annual revenue of Telesis Bio is $27.51M as on Dec 31, 2023.
Online platform offering life sciences reagents and kits. The companys products include the BioXp system, BioXp kits, and Benchtop reagents. Also, it develops vaccines, therapeutics, and diagnostics to combat the COVID-19 pandemic.
Telesis Bio offers BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA.
Yes, Telesis Bio is publicly traded on OTC under the ticker symbol TBIO.
Telesis Bio has made 1 acquisition, including Eton Bioscience.
Telesis Bio has 5 investors. Key investors include Oxford Finance, Broadoak Capital Partners, Novalis LifeSciences, Northpond Ventures, and M 185 Corporation.
Telesis Bio operates through Telesis Bio Inc..